Patients treated with Xofigo-Xtandi experienced a 5.6-month boost to median OS over those treated with Xtandi alone.

More than three decades ago, the U.S. Food and Drug Administration (FDA) approved Bacillus Calmette-Guérin (BCG) as the first immunotherapy against cancer. And it is still used today to treat ...

Emma Operacz was diagnosed with a rare cancer at 21. An unusual treatment and bone marrow donation from her sister saved her ...

For patients with mCRPC with bone metastases, the addition of radium-223 to enzalutamide therapy is associated with improved overall survival.

A new drug that works against the main types of primary bone cancer has been developed by researchers at the University of East Anglia and University of Sheffield. Cancer that starts in the bones, ...

Mayo Clinic in Jacksonville, Fla., offers a minimally invasive procedure to stabilize bones weakened by metastatic cancer, a technique available at few U.S. centers. The photodynamic bone ...

The International Osteoporosis Foundation (IOF) Bone and Cancer Working Group has released a comprehensive review detailing the often under-recognized impact of modern anti-cancer treatments on bone ...

Am J Health Syst Pharm. 2006;63(5):419-430. During resorption, growth factors and proteins released from osteoblast precursors and bone stimulate the differentiation, chemotaxis, and proliferation of ...

Positive results from clinical trials of an immune therapy in dogs with bone cancer have been used to fast-track the development of the drug to treat children with the same cancer. It highlights how ...